Alan R Lehmann Selected Research

Trichothiodystrophy Syndromes

10/2021	Metronidazole-Induced Hepatitis in a Teenager With Xeroderma Pigmentosum and Trichothiodystrophy Overlap.
1/2021	Protein instability associated with AARS1 and MARS1 mutations causes trichothiodystrophy.
4/2016	GTF2E2 Mutations Destabilize the General Transcription Factor Complex TFIIE in Individuals with DNA Repair-Proficient Trichothiodystrophy.
2/2015	TFIIH-dependent MMP-1 overexpression in trichothiodystrophy leads to extracellular matrix alterations in patient skin.
8/2006	An Xpd mouse model for the combined xeroderma pigmentosum/Cockayne syndrome exhibiting both cancer predisposition and segmental progeria.
11/2002	Reduced level of the repair/transcription factor TFIIH in trichothiodystrophy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alan R Lehmann Research Topics

Disease

14	Xeroderma Pigmentosum (Kaposi's Disease) 10/2021 - 01/2002
6	Trichothiodystrophy Syndromes 10/2021 - 11/2002
6	Neoplasms (Cancer) 01/2020 - 05/2003
3	Cockayne Syndrome (Syndrome, Cockayne) 10/2021 - 07/2005
2	Hypersensitivity (Allergy) 02/2016 - 08/2008
2	Melanoma (Melanoma, Malignant) 01/2015 - 02/2011
1	Reinfection 10/2021
1	Hepatitis 10/2021
1	Neurodevelopmental Disorders 01/2021
1	Hemangiosarcoma (Angiosarcoma) 01/2020
1	Skin Neoplasms (Skin Cancer) 01/2020
1	Chromosome Duplication 01/2017
1	Genomic Instability 01/2016
1	Neurologic Manifestations (Neurological Manifestations) 10/2015
1	Premature Aging 07/2014
1	Hearing Loss (Hearing Impairment) 07/2014
1	Telangiectasis (Telangiectasia) 07/2014
1	UV-Sensitive Syndrome 05/2012
1	Ataxia Telangiectasia (Louis Bar Syndrome) 01/2011
1	Carcinogenesis 02/2008
1	Progeria (Hutchinson Gilford Syndrome) 08/2006
1	Complementation Group D Xeroderma Pigmentosum 07/2005
1	Inborn Genetic Diseases (Disease, Hereditary) 02/2005
1	Complementation Group E Xeroderma Pigmentosum 11/2003

Drug/Important Bio-Agent (IBA)

10	Rad30 proteinIBA 06/2010 - 01/2002
8	Proteins (Proteins, Gene)FDA Link 01/2021 - 11/2003
5	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 01/2002
3	Pyrimidine DimersIBA 06/2010 - 11/2002
3	DNA-Directed DNA Polymerase (Polymerases, DNA)IBA 11/2004 - 11/2002
2	Transcription Factor TFIIHIBA 02/2015 - 11/2002
2	AntigensIBA 01/2015 - 02/2011
1	Metronidazole (Metric)FDA LinkGeneric 10/2021
1	Anti-Bacterial Agents (Antibiotics)IBA 10/2021
1	SulfurIBA 01/2021
1	Amino Acids FDA Link 01/2020
1	condensin complexes (condensin)IBA 01/2017
1	CohesinsIBA 01/2017
1	Transcription Factors (Transcription Factor)IBA 04/2016
1	transcription factor TFIIE (TFIIE)IBA 04/2016
1	1,2- di- (4- sulfamidophenyl)- 4- butylpyrazolidine- 3,5- dione (DSB)IBA 10/2015
1	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 01/2015
1	HeterochromatinIBA 11/2014
1	ChromatinIBA 11/2014
1	Proliferating Cell Nuclear Antigen (PCNA)IBA 07/2014
1	DNA-Directed RNA Polymerases (RNA Polymerase)IBA 05/2012
1	Phosphotransferases (Kinase)IBA 01/2011
1	A-Form DNA (A-DNA)IBA 06/2010
1	RNA (Ribonucleic Acid)IBA 08/2008
1	NucleotidesIBA 08/2006

Therapy/Procedure

1	Aftercare (After-Treatment) 10/2021
1	Immunotherapy 01/2020